Breaking News Instant updates and real-time market news.

PFE

Pfizer

$43.13

-0.4 (-0.92%)

, T

AT&T

$29.76

0.35 (1.19%)

18:01
11/21/18
11/21
18:01
11/21/18
18:01

Pfizer, Walmart, AT&T among companies pulling support for Hyde-Smith, ABC says

Pfizer (PFE) is the latest of several big-name corporations calling on Mississippi Republican Senator Cindy Hyde-Smith to give back their campaign donations after a video surfaced in which she discusses attending a "public hanging," ABC News reports. Hyde-Smith is currently in a runoff election race with Democrat Mike Espy, a former congressman who would be the state's first African-American senator since the 1800s, the report notes. "We condemn racism and bigotry in all its forms," Pfizer spokesperson Sharon Castillo told ABC News. Walmart yesterday said via Twitter that Hyde-Smith's comments "do not reflect the values of our company and associates" and said it was withdrawing its support and requesting a refund of all campaign donations, the report notes. In addition, AT&T (T), Boston Scientific (BSX), and Leidos (LDOS) have requested campaign refunds, the report says. Reference Link

PFE

Pfizer

$43.13

-0.4 (-0.92%)

T

AT&T

$29.76

0.35 (1.19%)

BSX

Boston Scientific

$34.59

0.54 (1.59%)

LDOS

Leidos

$63.09

0.65 (1.04%)

  • 21

    Nov

  • 27

    Nov

  • 27

    Nov

  • 29

    Nov

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 10

    Dec

PFE Pfizer
$43.13

-0.4 (-0.92%)

11/19/18
CANT
11/19/18
NO CHANGE
Target $53
CANT
Overweight
Pfizer's oncology assets are underappreciated, says Cantor Fitzgerald
Pfizer's oncology assets will make up 13% of its total 2018 sales and they will accelerate the company's sales growth for the foreseeable future, but these drugs are underappreciated, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Pfizer has said that through 2022 it expects 15 potential blockbusters to be launched, and oncology drugs are represented in these opportunities, the analyst points out. She sees upside to consensus estimates and keeps an Overweight rating on Pfizer with a $53 price target.
11/06/18
SBSH
11/06/18
INITIATION
Target $25
SBSH
Sell
Solid Biosciences initiated with a Sell at Citi
Citi analyst Joel Beatty started Solid Biosciences (SLDB) with a Sell rating and $25 price target. The analyst believes the gene therapy agents in clinical development for Duchenne muscular dystrophy by Sarepta (SRPT) and Pfizer (PFE) will leave little market share to Solid Bio's SGT-001. The analyst forecasts Sarepta capturing the largest share of the DMD gene therapy market, followed by Pfizer, and then Solid.
11/07/18
CHDN
11/07/18
NO CHANGE
Target $70
CHDN
Buy
uniQure price target raised to $70 from $50 at Chardan
Chardan analyst Gbola Amusa increased his price target on uniQure (QURE) to $70 from $50, stating that he believes the market is missing important dynamics in uniQure's favor over hemB competition from Pfizer (PFE) and Spark Therapeutics (ONCE). Amusa said uniQure's manufacturing is "much more scalable" than Pfizer's and he also believes uniQure's IP may cover the construct utilized by Pfizer. Amusa keeps a Buy rating on uniQure shares.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
T AT&T
$29.76

0.35 (1.19%)

10/22/18
10/22/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Intel (INTC) upgraded to Buy from Neutral at Nomura Instinet with analyst Romit Shah saying he believes Intel is a buy at current share levels. 2. AT&T (T) upgraded to Buy from Neutral at Tigress Financial with analyst Ivan Feinseth saying the upcoming launch of its high-speed 5G wireless communication network and the integration of Time Warner's content "creates a significant investment opportunity." 3. M&T Bank (MTB) upgraded to Overweight from Neutral at Piper Jaffray with analyst Kevin Barker saying this quarter, M&T's deposit base remained steady, its loan/deposit ratio declined and management felt confident the ratio would remain in the 95%-100% range for the foreseeable future. 4. Chipotle (CMG) upgraded to Outperform from Sector Perform at RBC Capital with analyst David Palmer saying while Q3 earnings may be "lackluster," he expects comps to improve from 4% to 6% through the second half of FY19 and raises his FY20 EPS vie to $16.30 from $15.86 on implied 3-turn multiple increase to 31-times forward earnings. 5. SAP (SAP) upgraded to Buy from Neutral at UBS with analyst Michael Briest saying the company deserves credit for sustaining 6%-10% underlying sales growth over the past 12 quarters, with "impressive" cloud growth at scale. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/18/18
NEED
10/18/18
NO CHANGE
Target $17
NEED
Buy
Adtran price target lowered to $17 at Needham on Q3 revenue slip
Needham analyst Richard Valera nudged his price target on Adtran (ADTN) lower to $17 from $18 and also lowered his FY19 EPS view to 15c from 42c after its Q3 revenues came in "light due to an explainable slip out of shipments to NBN". The analyst also notes the management's more downbeat view of its G.Fast program with AT&T (T), along with a generally more muted outlook for next year. Valera keeps a Buy on Adtran however, stating that although the stock is setting new 52-week lows on a series of disappointments, its valuation multiple of 1.1-times enterprise value to expected 2018 sales is supportive of the rating.
10/22/18
TIGR
10/22/18
UPGRADE
TIGR
Buy
AT&T upgraded to Buy from Neutral at Tigress Financial
Tigress Financial analyst Ivan Feinseth upgraded AT&T to Buy saying the upcoming launch of its high-speed 5G wireless communication network and the integration of Time Warner's content "creates a significant investment opportunity." AT&T will "significantly benefit from its merger with Time Warner creating one of the media industry's largest and most dynamic companies," Feinseth tells investors in a research note.
11/05/18
UBSW
11/05/18
DOWNGRADE
Target $34
UBSW
Neutral
Viacom downgraded to Neutral on tough AT&T renewal at UBS
As reported previously, UBS analyst John Hodulik downgraded Viacom (VIAB) to Neutral from Buy. The analyst believes the company will face a tough renewal with AT&T (T) in the second half of of 2019. He said Viacom has a low viewership relative to affiliate revenues, a lack of "must have" content, and a lack of carriage on other vMVPDs. Hodulik lowered his price target to $34 from $38 on Viacom shares.
BSX Boston Scientific
$34.59

0.54 (1.59%)

11/19/18
SPHN
11/19/18
NO CHANGE
Target $42
SPHN
Overweight
Boston Scientific price target raised to $42 from $40 at Stephens
Stephens analyst Chris Cooley raised his price target for Boston Scientific to 42 from $40 and reiterated an Overweight rating on the shares. The analyst believes the "requisite pieces" remain in place to enable Boston Scientific to potentially enhance the company's best-in-class organic revenue and non-GAAP earnings growth outlook as end markets continue to perform in-line, the portfolio continues to accrue share gains, planned new product launches and geographic expansion efforts stand to expand the addressable TAM, initiatives to increase margins by 50 to 100bps annually remain on track, and the company's enhanced financial position provides greater latitude for it to continue to invest in the core business while nimbly pursuing strategic opportunities as they may arise.
11/20/18
RHCO
11/20/18
NO CHANGE
Target $44
RHCO
Buy
Boston Scientific price target raised to $44 from $40 at SunTrust
SunTrust analyst Bruce Nudell raised his price target on Boston Scientific to $44 and kept his Buy rating, citing an update to his "relative valuation framework which regresses 3 year top-line expectations against relative forward multiple for larger cap med tech companies". The analyst has a positive view on the company after its diversified away from its dependence on the slow growth ICD/Pacer/Stent markets, stating that his 8.5% constant-currency top-line projection through "2021 includes inorganic growth from Claret, Augmenix & NxThera, and cash balance constraints fully alleviated in 2019".
11/20/18
SPHN
11/20/18
NO CHANGE
Target $42
SPHN
Overweight
Stephens reiterates Overweight rating on Boston Scientific after BTG deal
After Boston Scientific announced an agreement to acquire BTG plc for $4.2B, Stephens analyst Chris Cooley compared the "unexpected" deal to BSX's previous successful acquisition of AMS. As in the case of AMS, the Street is "surprised" by the scale and "out-of-the-box" nature of the proposed acquisition, but the company's core growth and margin profile will be enhanced and it will still have the ability to pursue more tuck-in acquisitions, Cooley tells investors. Following the deal announcement, he reiterates his Overweight rating and $42 price target on Boston Scientific shares.
11/20/18
PIPR
11/20/18
NO CHANGE
Target $40
PIPR
Overweight
Piper says Boston Scientific deal a 'headscratcher,' but should work out well
After Boston Scientific announced an agreement to acquire BTG for about $4.2B, Piper Jaffray analyst Matt O'Brien said the deal "looks like a headscratcher" at first glance, but he believes it will turn out to be a favorable transaction the more that he thinks about it. There is the clear opportunity to expand BTG's presence internationally and adding more therapeutic products in oncology provides a significant synergistic opportunity, O'Brien tells investors. Boston Scientific has proven capable of "acquiring solid assets and making them even better," said O'Brien, who believes that will be the case again. He maintains an Overweight rating and $40 price target on Boston Scientific shares.
LDOS Leidos
$63.09

0.65 (1.04%)

05/08/18
GSCO
05/08/18
DOWNGRADE
GSCO
Buy
Leidos downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Noah Poponak removed Leidos from his firm's Conviction List but keeps a Buy rating on the shares. The "moving targets and lack of consistency in working capital" on the cash flow statement have been surprising to the downside, Poponak tells investors in a research note. He notes Leidos has had four consecutive quarters of organic revenue decline. The analyst points out that, however, that Leidos is the least expensive Defense stock he covers. Poponak has an $82 price target for the shares.
06/18/18
GSCO
06/18/18
DOWNGRADE
Target $71
GSCO
Neutral
Leidos downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Noah Poponak downgraded Leidos to Neutral and lowered his price target for the shares to $71 from $82. The analyst cites "diminished confidence" in future estimates for his downgrade to Neutral.
06/21/18
WELS
06/21/18
NO CHANGE
WELS
Leidos may have opportunity to regain lost TSA business, says Wells Fargo
After the Washington Business Journal reported that the Transportation Security Administration has terminated a $578M contract awarded to Peraton, Wells Fargo analyst Ed Caso noted that Leidos is the incumbent providing logistical support services for security screening equipment. If the contract goes back to rebid, Leidos' transition agreement will likely need to be extended further and the company may have an opportunity to recapture the "notable" loss, added Caso, who has an Outperform rating on Leidos shares.
04/23/18
SBSH
04/23/18
UPGRADE
Target $71
SBSH
Buy
Citi upgrades Cerner to Buy on government EHR opportunity
Citi analyst Stephanie Demko upgraded Cerner (CERN) to Buy from Neutral with an unchanged price target of $71. The Department of Defense and Veterans Affairs are embarking on electronic health records upgrade projects worth greater than $14B, which is good for both Cerner and Leidos Holdings (LDOS), Demko tells investors in a research note. The analyst raised her price target for Leidos to $80 from $75 and keeps a Buy rating on the shares. Demko says contract delays at Veterans Affairs are an unfortunate, but normal, part of the government process. She believes both companies will address the critical needs facing the government.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.